Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3533 |
|
| Actual shortage: | 232 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3287 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DESMOPRESSIN | 0.2MG | TABLET | Resolved | 2024-12-05 | 2025-01-31 | 244883 |
| APO-DESVENLAFAXINE | 100MG | TABLET (EXTENDED-RELEASE) | Resolved | 2018-02-06 | 2018-07-03 | 38815 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2018-02-21 | 2018-03-08 | 40336 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2018-03-27 | 2018-07-03 | 44102 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2018-07-16 | 2018-10-02 | 55836 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-01-03 | 2019-01-17 | 71118 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-02-21 | 2019-04-05 | 76582 |
| APO-DESVENLAFAXINE | 100MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-04-10 | 2019-05-14 | 80926 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-04-30 | 2019-05-13 | 82837 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-08-21 | 2019-09-16 | 92019 |
| APO-DESVENLAFAXINE | 100MG | TABLET (EXTENDED-RELEASE) | Resolved | 2019-09-25 | 2019-11-04 | 94734 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2020-07-08 | 2020-07-18 | 119759 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2020-09-17 | 2020-10-08 | 124344 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2021-04-30 | 2021-06-07 | 138340 |
| APO-DESVENLAFAXINE | 100MG | TABLET (EXTENDED-RELEASE) | Resolved | 2021-09-17 | 2021-10-12 | 145831 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-01-07 | 2022-01-24 | 152301 |
| APO-DESVENLAFAXINE | 100MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-01-14 | 2022-02-18 | 152761 |
| APO-DESVENLAFAXINE | 100MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-01-14 | 2022-02-18 | 152764 |
| APO-DESVENLAFAXINE | 50MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-03-18 | 2022-04-06 | 156987 |
| APO-DESVENLAFAXINE | 100MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-03-25 | 2022-04-01 | 157298 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| MELPHALAN FOR INJECTION | 10ML 50MG | POWDER FOR SOLUTION KIT SOLUTION | Discontinued | 2022-03-23 | 2022-03-23 | 157136 |
| NAPROXEN SODIUM TABLETS | 220MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71228 |
| APO-PENTOXIFYLLINE SR | 400MG | TABLET (EXTENDED-RELEASE) | Discontinued | 2018-10-23 | 2022-01-27 | 65438 |
| APO-TEMAZEPAM | 15MG | CAPSULE | Discontinued | 2018-10-23 | 2019-01-14 | 65477 |
| APO-TEMAZEPAM | 30MG | CAPSULE | Discontinued | 2018-10-23 | 2019-01-07 | 65482 |
| TIGECYCLINE | 50MG | POWDER FOR SOLUTION | To be discontinued | 2019-06-21 | 2019-06-21 | 87218 |